Intellia Therapeutics, Inc.NTLANASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -42.54% | +104.76% | +51.27% | +78.79% |
| Gross Profit Growth | +0.00% | -37.07% | +226.87% | -815.26% | +32.06% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +12.60% | +8.37% | +6.97% | +9.09% | +6.40% |
| Weighted Average Shares Diluted Growth | +12.60% | +8.37% | +6.97% | +9.09% | +6.40% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -76.64% | -71.16% | -7.92% | +24.80% | +11.17% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -8.45% | -21.71% | -24.56% | -21.14% | -29.29% |
| Book Value per Share Growth | -26.26% | -30.54% | -31.14% | -28.73% | -27.63% |
| Debt Growth | +82.23% | +7.57% | -3.48% | -3.60% | -55.60% |
| R&D Expense Growth | +7.25% | -0.83% | -13.06% | -23.21% | -24.15% |
| SG&A Expenses Growth | +11.90% | -6.70% | -14.43% | +51.83% | +1.94% |